Enovis (NYSE:ENOV) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Enovis from “buy” to “hold,” although analysts overall maintain a “Moderate Buy” consensus and a $39.50 average price target.
• Enovis shares opened at $17.72, near their 12-month low of $16.70. The company exceeded quarterly earnings expectations, reporting $0.90 in EPS versus the $0.85 consensus and $582.78 million in revenue.
• Insiders purchased $449,599 worth of shares during the latest quarter, including significant buys by CEO Damien McDonald and insider Oliver Engert; institutional investors own 98.45% of the company.

Enovis (NYSE:ENOV - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other analysts also recently weighed in on ENOV. BTIG Research cut their price objective on shares of Enovis from $40.00 to $36.00 and set a "buy" rating on the stock in a research report on Tuesday, September 1st. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. BMO Capital Markets set a $27.00 price objective on Enovis in a report on Tuesday, September 1st. Weiss Ratings upgraded Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 21st. Finally, Evercore set a $32.00 target price on Enovis in a research note on Monday, July 6th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Enovis presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.50.

Enovis Stock Up 1.7%

Shares of Enovis stock opened at $17.72 on Friday. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -0.92 and a beta of 1.37. Enovis has a twelve month low of $16.70 and a twelve month high of $34.28. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The business's 50 day simple moving average is $21.74 and its 200-day simple moving average is $23.29.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm's revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts forecast that Enovis will post 3.15 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Damien Mcdonald purchased 13,035 shares of the company's stock in a transaction on Friday, September 4th. The shares were bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares of the company's stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Oliver Engert bought 2,660 shares of the business's stock in a transaction dated Friday, September 4th. The shares were bought at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the completion of the transaction, the insider directly owned 63,898 shares of the company's stock, valued at $1,201,282.40. This trade represents a 4.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 23,293 shares of company stock worth $449,599 over the last quarter. Insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc lifted its stake in Enovis by 5,590.5% in the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company's stock worth $25,000 after acquiring an additional 1,174 shares in the last quarter. Allworth Financial LP purchased a new position in Enovis during the 2nd quarter valued at about $36,000. Integrated Wealth Concepts LLC acquired a new position in shares of Enovis in the 2nd quarter valued at about $39,000. Public Employees Retirement System of Ohio acquired a new position in shares of Enovis in the 2nd quarter valued at about $48,000. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its position in shares of Enovis by 468,400.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company's stock worth $107,000 after purchasing an additional 4,684 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company's offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.